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Abstract
Introduction We investigated whether mRNA levels of E2F1, a
key transcription factor involved in proliferation, differentiation
and apoptosis, could be used as a surrogate marker for the
determination of breast cancer outcome.
Methods E2F1 and other proliferation markers were measured
by quantitative RT-PCR in 317 primary breast cancer patients
from the Stiftung Tumorbank Basel. Correlations to one another
as well as to the estrogen receptor and ERBB2 status and
clinical outcome were investigated. Results were validated and
further compared with expression-based prognostic profiles
using The Netherlands Cancer Institute microarray data set
reported by Fan and colleagues.
Results E2F1 mRNA expression levels correlated strongly with
the expression of other proliferation markers, and low values
were mainly found in estrogen receptor-positive and ERBB2-
negative phenotypes. Patients with low E2F1-expressing tumors
were associated with favorable outcome (hazard ratio = 4.3
(95% confidence interval = 1.8–9.9), P = 0.001). These results
were consistent in univariate and multivariate Cox analyses, and
were successfully validated in The Netherlands Cancer Institute
data set. Furthermore, E2F1 expression levels correlated well
with the 70-gene signature displaying the ability of selecting a
common subset of patients at good prognosis. Breast cancer
patients' outcome was comparably predictable by E2F1 levels,
by the 70-gene signature, by the intrinsic subtype gene
classification, by the wound response signature and by the
recurrence score.
Conclusion Assessment of E2F1 at the mRNA level in primary
breast cancer is a strong determinant of breast cancer patient
outcome. E2F1 expression identified patients at low risk of
metastasis irrespective of the estrogen receptor and ERBB2
status, and demonstrated similar prognostic performance to
different gene expression-based predictors.
Introduction
A variety of genes involved in breast cancer biology have been
studied and proposed as prognostic or predictive biomarkers,
but only a few of them, such as hormone receptors and
ERBB2, are used today to classify breast cancer patients and
to make treatment decisions in the clinical routine [1,2]. The
introduction of microarray analysis recently lead to a better
characterization of breast cancer on a molecular level, under-
ER = estrogen receptor; MFS = metastasis-free survival; NKI = The Netherlands Cancer Institute; PCR = polymerase chain reaction; RT = reverse 
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lining its biological heterogeneity and revealing that breast
tumors can be grouped into different subtypes with distinct
gene expression profiles and prognosis [3]. Some of these
subtypes confirmed the relevance of established differences
between phenotypes such as the estrogen receptor (ER) and
ERBB2 status, but also identified novel breast cancer sub-
types or prognostic signatures of potential clinical value [3-7].
Although little overlap was observed between these gene sig-
natures at the level of individual genes, recent data indicate
that the underlying biological processes and pathways might
be common [8-10].
In terms of tumor biology, proliferation has been recognized as
a distinct hallmark of cancer and as an important determinant
of cancer outcome [11-13]. Increased tumor cell proliferation
is accompanied by cell matrix remodeling and neo-angiogen-
esis, which together form the basis for an aggressive tumor
phenotype [14,15]. This observation was further underlined by
recent reports showing that several genes involved in gene
signatures discriminating clinically relevant breast cancer sub-
types were related to proliferation [3,4,9,16,17].
In the context of breast cancer molecular screening, we
recently investigated by quantitative RT-PCR the expression of
60 tumor-related genes in various subsets of breast cancers
from the Stiftung Tumorbank Basel (STB) [18,19]. This gene
set also comprised several genes involved in proliferation such
as thymidilate synthase (TYMS), thymidine kinase 1 (TK1),
topoisomerase 2-alpha (TOP2A), survivin (BIRC5) and the
transcription factor E2F1. Since these genes strongly corre-
lated to one another and since the assessment of a single
gene able to accurately predict breast cancer patients' out-
come would represent major advantages for standard clinical
use, we focused our efforts on the evaluation of E2F1 tran-
script levels as surrogate marker for proliferation. This tran-
scription factor is well known for being involved in the cyclin/
cyclin-dependent kinase/retinoblastoma pathway and for con-
trolling the expression of more than 1,000 genes involved in
cell proliferation, differentiation and apoptosis [20-23]. In a set
of 317 primary breast cancers patients with known clinical out-
come (STB data set), we evaluated E2F1 mRNA expression
levels with respect to other proliferation markers, ER and
ERBB2 status and clinical outcome. All results obtained in our
collective were subsequently validated in The Netherlands
Cancer Institute (NKI) microarray data set comprising 295
breast cancer patients. Moreover, the prognostic value of
E2F1 was compared with the 70-gene prognostic signature,
and with other gene expression-based predictors such as the
intrinsic subtypes, the wound response signature and the
recurrence score available as reported by Fan and colleagues
using the same NKI data set [8].
Methods
Study populations
Patients and methods have been described previously [18].
The 317 primary breast cancer tissue samples were obtained
from the STB, Switzerland and were analyzed by quantitative
RT-PCR (STB data set). The previously published microarray
breast cancer data set reported by Van de Vijver and col-
leagues (NKI data set) [5] was used for validation and compar-
ative analysis as reported by Fan and colleagues [8]. Major
differences between the two study populations included the
patient age, nodal status, adjuvant therapy and methodology
(quantitative RT-PCR versus Agilent microarray). Detailed
patient and tumor characteristics are summarized in Table 1.
Quantitative real-time PCR analysis
Gene expression measurements by quantitative RT-PCR were
performed as reported previously [24]. Total RNA was
extracted using the RNAeasy Mini Kit (Qiagen, Hilden, Ger-
many) and was quality-checked on a Bioanalyzer 2100 (Agi-
lent Technologies, Palo Alto, CA, USA). High-quality RNA
samples were reverse-transcribed and PCR was carried out in
40 cycles on a ABI Prism 7000 using 2× SYBR Green I Mas-
ter Mix (Applied Biosystems, Forster City, CA, USA). Relative
gene expression quantities (Δ[Ct] values) were obtained by
normalization against ribosomal 18S RNA.
Statistical analysis
For the STB study the ER status was defined based on the
mRNA level as reported previously [24], and for the NKI data
set the status was defined as provided by the authors [5,8].
The ERBB2 status was determined in both the STB and NKI
data sets using mRNA expression levels for all study popula-
tions as previously described by Urban and colleagues [18].
The prognostic value of biomarkers was assessed by univari-
ate and multivariate Cox analysis against metastasis-free sur-
vival (MFS), and in different patient subgroups according to
the ER and ERBB2 status. The association of E2F1 with MFS
in particular was assessed by univariate Cox analysis for vari-
ous cutoff values (data not shown). For all subsequent analy-
sis, the 30th percentile was used as the cutoff point for E2F1.
Survival probabilities for MFS were calculated according to
the Kaplan–Meier method, and group differences were
assessed by the logrank test. Multivariate P values were based
on Wald statistics. Statistical analysis was performed with 'R'
statistical software version 2.0.1 using the 'survival' package
[25].
Results
E2F1 correlated with other proliferation markers and 
clinical outcome
A strong and significant correlation was found between the
five proliferation markers analyzed in the STB data set (Table
2). Univariate Cox regression analysis demonstrated a signifi-
cant association of E2F1 as well as TYMS, TK1, TOP2A andAvailable online http://breast-cancer-research.com/content/9/3/R33
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Table 1
Patient and tumor characteristics
Characteristic Stiftung Tumorbank Basel data set The Netherlands Cancer Institute data set
Method Quantitative RT-PCR Agilent Microarray
n 317 295
Age
Mean/median (years) 60/59 44/44
≤ 40 years 20 (6%) 75 (25%)
41–55 years 110 (35%) 220 (75%)
≥ 56 years 187 (59%) 0 (0%)
pT stage
pT1 100 (32%) 155 (53%)
pT2 183 (58%) 140 (47%)
pT3/4 33 (10%) 0
pN status
Negative 161 (54%) 151 (51%)
Positive 136 (46%) 144 (49%)
Unknown 20 0
Histological grade
1 (good) 28 (9%) 75 (25%)
2 (intermediate) 137 (46%) 101 (34%)
3 (poor) 133 (45%) 119 (41%)
Unknown 19 0
Estrogen receptor statusa
Positive 231 (73%) 226 (77%)
Negative 86 (27%) 69 (23%)
ErbB2 status
Positive 70 (22%) 52 (18%)
Negative 247 (78%) 243 (82%)
Adjuvant therapy
None 60 (20%) 165 (56%)
Hormone 135 (44%) 20 (7%)
Chemotherapy 72 (24%) 90 (30%)
Combination 38 (12%) 20 (7%)
Total 245 (80%) 130 (44%)
Unknown 12 0
Follow-up
Events (metastases) 57 (18%) 101 (34%)
Mean/median metastasis-free survival (years) 3.7/3.6 7.3/6.8
Data presented as n (%) unless stated otherwise. aEstrogen receptor positive, ≥ 20 fmol/mg protein (enzyme immunoassay) for the Stiftung 
Tumorbank Basel data set; for The Netherlands Cancer Institute study, see [5,6]Breast Cancer Research    Vol 9 No 3    Vuaroqueaux et al.
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BIRC5 expression levels with distant MFS (Table 2). Similar
results were observed in the NKI data set (data not shown). In
the NKI data set we also investigated Ki67. The RNA expres-
sion levels of this proliferation marker were positively corre-
lated with E2F1 (correlation coefficient = 0.46) and were
borderline significant (P = 0.02) in univariate Cox regression
analysis.
Distinct E2F1 expression patterns according to ER and 
ERBB2 status determined the clinical outcome
Scatter plots of E2F1 versus ER and ERBB2 expression levels
in the STB data set (Figure 1a,b) revealed that ER-negative
and ERBB2-positive breast tumors typically expressed high
levels of E2F1, whereas in contrast low E2F1 levels (below the
30th percentile of its distribution in this collective) were
detected almost exclusively in ER-positive and ERBB2-nega-
tive breast tumors. The same pattern was observed in the NKI
data set (Figure 1c,d). Similar scatter plots were obtained ana-
lyzing the other proliferation markers (data not shown).
Cox univariate survival analysis performed in subsets of
patients according to their ER and ERBB2 status showed that
E2F1 correlated with MFS in ER-positive and ERBB2-nega-
tive tumors, but not in ER-negative and ERBB2-positive
tumors (data not shown). Combined Kaplan–Meier analysis
using E2F1 and the ER or ERBB2 status revealed that
patients whose tumors expressed low E2F1 levels, a situation
found mainly in ER-positive and ERBB2-negative phenotypes,
were associated with favorable outcome, whereas patients
with tumors expressing high E2F1 levels revealed a poor out-
come independent of the ER and ERBB2 status (Figure 1e-h).
E2F1 correlated well with the 70-gene signature
The majority of the patients in the NKI data set assigned to the
good-prognosis group by the 70-gene signature expressed
low E2F1 levels and were found to be ER-positive or ERBB2-
negative (Figure 2a,b). In addition, there was a strong correla-
tion (r = 0.67) between E2F1 and the 70-gene signature (Fig-
ure 2c). In particular, 77% (69 out of 90) of patients with low
E2F1-expressing tumors overlapped with patients assigned to
the good-prognosis group by the 70-gene signature and were
indeed found to be at the lowest risk of metastatic events.
Patients with low E2F1 and a poor-prognosis signature or
patients with high E2F1 and a good-prognosis signature had
a comparable incidence of metastases (Table 3).
E2F1 stratification showed similar prognostic value as 
the 70-gene and other gene-based predictors
Kaplan–Meier analysis displayed the similar prognostic value
of E2F1 and the 70-gene signature (hazard ratio = 5.1 (95%
confidence interval = 2.7–9.8) and hazard ratio = 4.6 (95%
confidence interval = 2.7–7.8), respectively; Figure 3a). We
obtained similar results (Figure 3b–d) when E2F1 levels were
compared with the breast cancer intrinsic subtypes [3], with
the recurrence score [17] and with the wound response sig-
nature [7], all of these gene expression-based predictors
being reported by Fan and colleagues in the NKI data set [8].
E2F1 was a strong and independent survival factor in 
multivariate analysis
Multivariate survival analysis including E2F1, nodal status,
grade, tumor size, age, ER and ERBB2 status, and treatments
revealed that only E2F1 and nodal status retained independ-
ent prognostic value in the STB data set (Table 4), and that
E2F1, nodal status, tumor size, age and chemotherapy were
significant in the NKI data set (Table 5). We performed a
second multivariate Cox model including additionally the 70-
gene signature in the NKI data set (Table 5), reconfirming that
E2F1 and the 70-gene signature were significant and additive
predictive survival factors together with the nodal status,
tumor size and chemotherapy.
Discussion
In the present study we demonstrated that the assessment of
E2F1 mRNA as a surrogate proliferation marker is a strong
determinant of breast cancer outcome, particularly suitable for
identifying patients at very low risk of metastasis, comparable
with gene expression-based signatures such as the 70-gene
signature. The prognostic component of the ER and ERBB2
status as well as different gene signatures were found to be
Table 2
Correlation among different proliferation markers in the Stiftung Tumorbank Basel data set and association with survival
Correlationa Univariate Cox 
regressionb (P value)
E2F1 BIRC5 TOP2A TK1
E2F1 - <0.001
BIRC5 0.84 0.001
TOP2A 0.78 0.76 <0.001
TK1 0.79 0.88 0.67 0.018
TYMS 0.81 0.80 0.71 0.77 0.005
aPearson correlation coefficient, all P < 0.05. bMetastasis-free survival.Available online http://breast-cancer-research.com/content/9/3/R33
Page 5 of 10
(page number not for citation purposes)
Figure 1
Estrogen receptor and ERBB2 versus E2F1 expression levels Estrogen receptor and ERBB2 versus E2F1 expression levels. Scatter plots of estrogen receptor (ER) ESR1 and ERBB2 versus E2F1 expres-
sion levels in (a), (b) the Stiftung Tumorbank Basel data (STB) set and (c), (d) The Netherlands Cancer Institute (NKI) data set. Open circles, no 
metastasis; filled circles, metastasis. Vertical lines, cutoff values for the estrogen receptor (ER) and ERBB2 status, respectively; horizontal lines, 30th 
percentile for E2F1. Combined Kaplan–Meier analysis (metastasis-free survival) using the ER or ERBB2 status and E2F1 (30th percentile) in (e), (f) 
the STB data set and (g), (h) the NKI data set. Labels of the survival curves correspond to the groups as indicated on the respective scatter plot. CI, 
95% confidence interval; HR, hazard ratio.Breast Cancer Research    Vol 9 No 3    Vuaroqueaux et al.
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strongly related to tumor proliferation. In fact, a large subset of
patients classified with very favorable outcome shared a
common molecular tumor phenotype characterized by ER-
positive and/or ERBB2-negative status and low proliferation
(low levels of E2F1 as well as BIRC5,TYMS,TOP2A and TK1).
Moreover, the results obtained in our data set analyzed by
quantitative RT-PCR were successfully validated in an inde-
pendent breast cancer data set using microarray technology.
Sotiriou and colleagues developed a gene expression grade
index able to reclassify breast cancer patients with tumor his-
tological grade 2 into groups with high risk of recurrence ver-
sus low risk [9]. The gene expression grade index was
developed on the basis of the analysis of five breast cancer
microarray data sets including more than 600 tumors, from
which the authors extracted a list of 242 genes associated
with tumor grade and predicting patient outcome. Most of
these genes were related to proliferation and cell survival,
such as E2F1 and MKI67, BIRC5, TOP2A and STK6, all being
highly correlated and providing similar prognostic information.
In our study, we demonstrated that the detection of a single
gene is sufficient to select tumors at low proliferation. A single
gene assessment requires high RNA quality from fresh (fro-
zen) tissue, however, and might be insufficient in cases of
more heterogeneous RNA quality (for example, RNA from par-
affin-embedded tissues).
Breast cancer has been successfully classified using microar-
rays into clinically relevant subgroups based on variations in
gene expression patterns. Sorlie and colleagues showed that
ER-negative tumors grouped into basal-like and ERBB2 sub-
types, both with poor prognosis [3]. In contrast, ER-positive
breast cancers could be classified into luminal A and luminal
B subtypes with significantly distinct prognosis: luminal A
tumors displayed favorable outcome, whereas survival of
patients with luminal B tumors was poor and comparable with
those of the ER-negative ERBB2 and basal subtypes [3]. Our
classification in the NKI data set revealed that 81% of the
tumors expressing low E2F1 levels (below this study's cutoff
point) corresponded with luminal A subtype as defined by Fan
and colleagues [8], and subsequently had similar prognostic
value (Figure 3b).
Van de Vijver and colleagues used a 70-gene prognostic sig-
nature to discriminate patients with good prognosis and poor
prognosis [5], which according to our analysis strongly corre-
lated with E2F1 expression levels. As shown in Figure 2,
patients defined as of good prognosis by the 70-gene signa-
Table 3
Concordance of E2F1 with the 70-gene signature in The Netherlands Cancer Institute data set
Proliferation status (E2F1) NKI 70-gene signature prognosis
Good Poor Total
E2F1 ≤ p30 4/69 (5.7%) 6/21 (28.6%) 10/90 (11.1%)
E2F1 > p30 12/46 (26.1%) 79/159 (49.6%) 91/205 (44.4%)
Total 16/115 (13.9%) 85/180 (47.2%) 101/295 (34.2%)
The percentage indicates the number of metastatic events over the number of cases in each group.
Figure 2
Comparison of E2F1 and the 70-gene signature in The Netherlands Cancer Institute data set Comparison of E2F1 and the 70-gene signature in The Netherlands Cancer Institute data set. (a), (b) Scatter plots of estrogen receptor (ER = 
ESR1) and ERBB2 versus E2F1 expression levels. Open circles, poor-prognosis group as defined by [5]; filled circles, good-prognosis group [5]. 
(c) Correlation between the 70-gene prognostic signature and E2F1. Open circles, no metastasis; filled circles, metastasis.Available online http://breast-cancer-research.com/content/9/3/R33
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ture had tumors expressing low E2F1 levels and were mainly
ER-positive. Despite all observed correlations, multivariate
Cox analysis of the NKI data set showed that E2F1 levels and
the 70-gene prognostic signature retained additive signifi-
cance when both covariates were included (Table 5). This is
probably due to the fact that both markers classified, in
addition to the overlapping patients at very low risk, patients at
similar but higher risk who would not have been selected by
either classifier alone (Table 3). Furthermore, we found that
almost all ERBB2-positive and ER-negative tumors expressed
high levels of E2F1 and were classified as of poor prognosis
according to the 70-gene signature – suggesting an explana-
tion of why Espinosa and colleagues were unsuccessful in
improving the accuracy of the 70-gene signature by incorpo-
rating additional genes such as ERBB2 [26].
Fan and colleagues [8] recently demonstrated that the differ-
ent gene-expression-based predictors including the 70 gene-
signature, the intrinsic subtypes, the wound signature and the
recurrence score were highly concordant to evaluate breast
cancer outcome. Our analysis revealed that low proliferation
as quantified by low levels of E2F1 represented a common
determinant of patients with good prognosis (Figures 2 and 3).
It has to be noted that the prognostic value of E2F1 was inde-
pendent of the nodal status. Indeed, 40% of the STB tumors
and 50% of the NKI tumors with low E2F1 expression levels
belonged to nodal-positive patients at very low risk of metas-
tases, reconfirming the impact of proliferation recently
reported in a study evaluating breast cancer patients with 10
and more positive lymph nodes [27,28].
The STB and NKI data sets differed in adjuvant treatment
modalities; in general, patients of the STB collective were
older and consequently received more hormone therapy but
less chemotherapy as compared with patients of the NKI
collective. In this context, it has to be emphasized that treat-
ment regiments were chosen independent of the E2F1 status
(Additional file 1) and that E2F1 levels retained predictive sur-
vival significance in patients with and without different adju-
vant treatments (Additional file 2). Multivariate analyses,
however, revealed different treatment impacts in the two data
sets (Tables 4 and 5). In the STB collective, chemotherapy
was particularly significant in univariate Cox analysis but was
nonsignificant in multivariate Cox models, suggesting that
information about the higher risk cases receiving chemother-
apy is already included in the combination of the other covari-
ates. Since E2F1 is co-expressed or regulates genes such as
TYMS, TK1 and TOP2A, which were mechanistically linked
with response to 5-fluorouracil and anthracycline-based ther-
apy [16,29-32], however, our results with respect to specific
chemotherapy response should be further investigated.
Figure 3
Kaplan–Meier analysis of metastasis-free survival Kaplan–Meier analysis of metastasis-free survival. Kaplan–Meier analysis (metastasis-free survival) using (a) E2F1 expression (30th percentile) 
and the 70-gene signature, (B) intrinsic subtypes, (c) the recurrence score (Rsu), and (b) the wound response signature. CI, 95% confidence inter-
val; HR, hazard ratio.Breast Cancer Research    Vol 9 No 3    Vuaroqueaux et al.
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Conclusion
Since accurate monitoring of proliferation assessing the
mRNA E2F1 levels together with the determination of the ER
and ERBB2 status can be performed easily by quantitative RT-
PCR even in small amounts of tissue such as core biopsies
[19], we encourage the inclusion of such analyses in protocols
of ongoing clinical and translational research investigations,
including predictive studies with respect to specific
chemotherapies.
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Table 4
Univariate and multivariate Cox analyses in the Stiftung Tumorbank Basel data set (n = 317)
Factor Univariate metastasis-free survival Multivariate metastasis-free survival
Hazard ratio (95%
confidence interval)
P value Hazard ratio (95%
confidence interval)
P value
E2F1 (>p30 versus ≤ p30) 4.27 (1.83–9.96) 0.001 2.95 (1.10–7.93) 0.032
Grade (3 versus 1 + 2) 2.03 (1.17–3.51) 0.011 1.56 (0.77–3.14) 0.213
Estrogen receptor status (positive versus negative) 0.64 (0.37–1.12) 0.120 1.21 (0.56–2.61) 0.625
ERBB2 status (positive versus negative) 1.69 (0.98–2.92) 0.058 1.41 (0.70–2.81) 0.335
pN (>3 nodes versus ≤ 3 nodes) 3.14 (1.76–5.61) <0.001 2.36 (1.14–4.88) 0.021
Size (>2 cm versus ≤ 2 cm) 1.95 (1.05–3.62) 0.036 1.19 (0.58–2.43) 0.641
Age (≤ 40 years versus >40 years) 0.30 (0.15–0.59) 0.001 0.59 (0.24–1.43) 0.246
Chemotherapy 2.65 (1.54–4.55) <0.001 1.27 (0.45–3.59) 0.654
Hormone therapy 0.50 (0.28–0.88) 0.017 0.76 (0.27–2.17) 0.605
70-gene signature (poor versus good prognosis) Not available Not available Not available Not available
Table 5
Univariate and multivariate Cox analyses in The Netherlands Cancer Institute data set (n = 295)





P value With 70-gene signature Without 70-gene signature
Hazard ratio (95%
confidence interval)
P value Hazard ratio (95%
confidence interval)
P value
E2F1 (>p30 versus ≤ p30) 5.09 (2.65–9.78) <0.001 3.76 (1.90–7.45) <0.001 2.47 (1.20–5.10) 0.014
Grade (3 versus 1 + 2) 2.38 (1.60–3.52) <0.001 1.28 (0.82–2.00) 0.277 1.02 (0.65–1.60) 0.931
Estrogen receptor status (positive versus 
negative)
0.54 (0.36–0.83) 0.005 0.99 (0.61–1.59) 0.956 1.11 (0.70–1.78) 0.658
ERBB2 status (positive versus negative) 1.61 (1.01–2.57) 0.045 1.35 (0.82–2.21) 0.234 1.28 (0.78–2.09) 0.330
pN (>3 nodes versus ≤ 3 nodes) 2.20 (1.37–3.53) 0.001 2.35(1.32–4.21) 0.004 2.69 (1.47–4.91) 0.001
Size (>2 cm versus ≤ 2 cm) 2.08 (1.39–3.10) <0.001 1.70 (1.12–2.58) 0.013 1.73 (1.14–2.62) 0.010
Age (≤ 40 years versus >40 years) 0.50 (0.33–0.75) 0.001 0.59 (0.38–0.89) 0.013 0.67 (0.43–1.02) 0.063
Chemotherapy 0.79 (0.52–1.19) 0.254 0.61 (0.38–1.00) 0.051 0.55 (0.33–0.91) 0.020
Hormone therapy 0.58 (0.28–1.19) 0.139 0.60 (0.28–1.27) 0.181 0.58 (0.27–1.23) 0.157
70-gene signature (poor versus good 
prognosis)
4.55 (2.67–7.77) <0.001 Not included Not included 2.78 (1.49–5.21) 0.001
aMultivariate metastasis-free survival calculated once with and once without the 70-gene signature.Available online http://breast-cancer-research.com/content/9/3/R33
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